📣 VC round data is live. Check it out!

Trinity Biotech Valuation Multiples

Discover revenue and EBITDA valuation multiples for Trinity Biotech and similar public comparables like Iconovo, Spineguard, Lifecare, Renalytix and more.

Trinity Biotech Overview

About Trinity Biotech

Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.


Founded

1992

HQ

Ireland

Employees

401

Financials (FY)

Revenue: $44M
EBITDA: ($21M)

EV

$144M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Trinity Biotech Financials

Trinity Biotech reported last fiscal year revenue of $44M and negative EBITDA of ($21M).

In the same fiscal year, Trinity Biotech generated $17M in gross profit, ($21M) in EBITDA losses, and had net loss of ($37M).

Revenue (LTM)


Trinity Biotech P&L

In the most recent fiscal year, Trinity Biotech reported revenue of $44M and EBITDA of ($21M).

Trinity Biotech is unprofitable as of last fiscal year, with gross margin of 39%, EBITDA margin of (49%), and net margin of (85%).

See analyst estimates for Trinity Biotech
Last FY202320242025202620272028
Revenue$44M$57M$62M$44M
Gross Profit$17M$19M$21M$17M
Gross Margin39%34%35%39%
EBITDA($21M)($25M)($17M)($21M)
EBITDA Margin(49%)(44%)(27%)(49%)
EBIT Margin(26%)(28%)(25%)(26%)
Net Profit($37M)($24M)($32M)($37M)
Net Margin(85%)(42%)(52%)(85%)
Net Debt$119M

Financial data powered by Morningstar, Inc.

Trinity Biotech Stock Performance

Trinity Biotech has current market cap of $11M, and enterprise value of $144M.

Market Cap Evolution


Trinity Biotech's stock price is $0.57.

Trinity Biotech share price decreased by 6.3% in the last 30 days, and by 12.1% in the last year.

Trinity Biotech has an EPS (earnings per share) of $-1.85.

See more trading valuation data for Trinity Biotech
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$144M$11M-0.9%-6.3%-21.5%-12.1%$-1.85

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Trinity Biotech Valuation Multiples

Trinity Biotech trades at 3.3x EV/Revenue multiple, and (6.7x) EV/EBITDA.

See NTM and 2027E valuation multiples for Trinity Biotech

EV / Revenue (LTM)


Trinity Biotech Financial Valuation Multiples

As of May 20, 2026, Trinity Biotech has market cap of $11M and EV of $144M.

Trinity Biotech has a P/E ratio of (0.3x).

Last FY202320242025202620272028
EV/Revenue3.3x2.5x2.3x3.3x
EV/EBITDA(6.7x)(5.8x)(8.5x)(6.7x)
EV/EBIT(12.6x)(9.1x)(9.3x)(12.6x)
EV/Gross Profit8.5x7.4x6.7x8.5x
P/E(0.3x)(0.5x)(0.4x)(0.3x)
EV/FCF(11.9x)(10.1x)(10.1x)(11.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Trinity Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Trinity Biotech Margins & Growth Rates

In the most recent fiscal year, Trinity Biotech reported gross margin of 39%, EBITDA margin of (49%), and net margin of (85%).

See estimated margins and future growth rates for Trinity Biotech

Trinity Biotech Margins

Last FY20242025202720282029
Gross Margin39%35%39%
EBITDA Margin(49%)(27%)(49%)
EBIT Margin(26%)(25%)(26%)
Net Margin(85%)(52%)(85%)
FCF Margin(28%)(23%)(28%)

Trinity Biotech Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth8%(29%)
Gross Profit Growth10%(21%)
EBITDA Growth(32%)26%
EBIT Growth(3%)(26%)
Net Profit Growth32%18%
FCF Growth(0%)(15%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Trinity Biotech Operational KPIs

Trinity Biotech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Access forward-looking KPIs for Trinity Biotech
Last FY202320242025202620272028
Revenue per Employee$0.1M
Opex per Employee$0.1M
R&D Expenses to Revenue8%8%7%8%
Opex to Revenue65%62%60%65%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Trinity Biotech Competitors

Trinity Biotech competitors include Iconovo, Spineguard, Lifecare, Renalytix, Jana Medical Company, Allurion, Scandinavian Medical, Subgen AI, Scandinavian ChemoTech and Arcoma.

Most Trinity Biotech public comparables operate across Medical Devices.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Iconovo59.8x5.6x(2.0x)(2.0x)
Spineguard2.4x2.2x(8.4x)(12.5x)
Lifecare1807.3x106.0x(1.8x)(2.1x)
Renalytix3.4x3.4x(0.5x)
Jana Medical Company0.8x(2.1x)
Allurion2.3x
Scandinavian Medical0.6x0.6x12.9x17.5x
Subgen AI0.4x(9.9x)

This data is available for Pro users. Sign up to see all Trinity Biotech competitors and their valuation data.

Start Free Trial

Trinity Biotech M&A Activity

Trinity Biotech has acquired 2 companies to date.

Last acquisition by Trinity Biotech was on October 25th 2024. Trinity Biotech acquired EpiCapture for $3M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Trinity Biotech

EpiCapture
Metabolomic Diagnostics
Description
EpiCapture is a diagnostics company developing non-invasive urine-based tests for detecting aggressive prostate and bladder cancers. Based in the United Kingdom, the firm employs epigenetic biomarker technology to identify high-risk cases with greater than 90 percent specificity in early validation studies. Its assays target methylation patterns associated with tumor progression, enabling earlier intervention than traditional PSA screening. EpiCapture collaborates with NHS trusts and urology clinics for clinical deployment, focusing on improving patient outcomes through liquid biopsy methods. The platform processes samples in under two hours using standard lab equipment.
Metabolomic Diagnostics is a deep-tech company developing biomarker-based diagnostics for complex diseases like cancer and neurodegeneration. Headquartered in the United Kingdom, it pipelines panels from discovery to clinical assays using mass spectrometry. The firm validates tests for lab integration with partners in NHS and private clinics. Metabolomic Diagnostics targets multi-omics signatures for personalized medicine applications.
HQ CountryIrelandIreland
HQ City
Dublin
Cork
Deal Date25 Oct 202424 Sep 2024
Valuation$3M$1M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Trinity Biotech acquisitions and their M&A valuation multiples.

Start Free Trial

Trinity Biotech Investment Activity

Trinity Biotech has invested in 2 companies to date.

Latest investment by Trinity Biotech was on January 15th 2025. Trinity Biotech invested in Novus Diagnostics in their $5M Seed round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by Trinity Biotech

Novus Diagnostics
Novus Diagnostics
imaware
Description
Novus Diagnostics is a medtech company developing a sample-to-answer diagnostic platform for sepsis that processes whole blood samples. Its device rapidly detects and classifies bacterial and fungal pathogens within one hour, aiding critical care decisions in hospitals. Headquartered in Belfast, Northern Ireland, Novus focuses on point-of-care testing to reduce sepsis mortality rates through early identification.
Novus Diagnostics is a medtech company developing a sample-to-answer diagnostic platform for sepsis that processes whole blood samples. Its device rapidly detects and classifies bacterial and fungal pathogens within one hour, aiding critical care decisions in hospitals. Headquartered in Belfast, Northern Ireland, Novus focuses on point-of-care testing to reduce sepsis mortality rates through early identification.
imaware is a health technology company offering at-home diagnostic tests for conditions in men's health, women's health, allergies, autoimmune diseases, genetics, and infectious diseases like COVID-19. Its patient platform includes CLIA/CAP-certified lab analysis, telehealth consultations, and logistics for seamless care delivery. imaware partners with employers, providers, and brands to provide monitoring solutions across the United States. The digitally-native model supports screening, therapy guidance, and compliance, headquartered in New York with nationwide shipping.
HQ CountryIrelandIrelandUnited States
HQ City
Dublin
Dublin
Austin, TX
Deal Date15 Jan 202525 Oct 20249 Jan 2023
RoundSeedStrategic investmentSeries A
Raised$5M$3M$6M
InvestorsBusiness Venture Partners; Irrus Investments; Trinity BiotechTrinity BiotechTrinity Biotech
Valuationundisclosed$20Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Trinity Biotech investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Trinity Biotech

When was Trinity Biotech founded?Trinity Biotech was founded in 1992.
Where is Trinity Biotech headquartered?Trinity Biotech is headquartered in Ireland.
How many employees does Trinity Biotech have?As of today, Trinity Biotech has over 401 employees.
Who is the CEO of Trinity Biotech?Trinity Biotech's CEO is John Gillard.
Is Trinity Biotech publicly listed?Yes, Trinity Biotech is a public company listed on Nasdaq.
What is the stock symbol of Trinity Biotech?Trinity Biotech trades under TRIB ticker.
When did Trinity Biotech go public?Trinity Biotech went public in 1992.
Who are competitors of Trinity Biotech?Trinity Biotech main competitors include Iconovo, Spineguard, Lifecare, Renalytix, Jana Medical Company, Allurion, Scandinavian Medical, Subgen AI, Scandinavian ChemoTech, Arcoma.
What is the current market cap of Trinity Biotech?Trinity Biotech's current market cap is $11M.
What is the current revenue of Trinity Biotech?Trinity Biotech's last fiscal year revenue is $44M.
What is the current EV/Revenue multiple of Trinity Biotech?Current revenue multiple of Trinity Biotech is 3.3x.
Is Trinity Biotech profitable?No, Trinity Biotech is not profitable.
How many companies Trinity Biotech has acquired to date?As of May 2026, Trinity Biotech has acquired 2 companies.
What was the largest acquisition by Trinity Biotech?$3M acquisition of EpiCapture on 25th October 2024 was the largest M&A Trinity Biotech has done to date.
What companies Trinity Biotech acquired?Trinity Biotech acquired EpiCapture and Metabolomic Diagnostics.
In how many companies Trinity Biotech has invested to date?As of May 2026, Trinity Biotech has invested in 2 companies.
What was the last Trinity Biotech investment?On 15th January 2025 Trinity Biotech invested in Novus Diagnostics, participating in a $5M Seed round, alongside Business Venture Partners and Irrus Investments.
In what companies Trinity Biotech invested in?Trinity Biotech invested in imaware and Novus Diagnostics.

See public comps similar to Trinity Biotech

Lists including Trinity Biotech

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial